Canada markets close in 3 hours 20 minutes

Greenwich LifeSciences, Inc. (GLSI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.84-0.12 (-1.26%)
As of 12:34PM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • J
    Jessica
    I don’t know how I ever traded without using http://bullishstocks.tech. I look forward to their daily emails each morning that list pre-market movers based on thoroughly researched stock market and world news. I highly recommend anyone who invests in the stock market!
  • C
    Cured
    $SLS conversation
    Can you research my posts for the time before $glsi was up 2,400% in a single trading session. p2 data presented at sabcs was published 5 months before the market took notice. I think the market is missing number 1.of 8 on the catalyst list. Final phase 2, 3 year old joint analysis - Checkpoint blockade + wt1 t cells, final results could be in the next 2 days, based Gabrieles posts. A late breaking abstract Pr could take this 40m mcap to 100 or 400 if Merck puts in upfront money for a license. Last update - median survival not yet met at 10m of survival, with no black bx SA's. Already an effective treatment.
  • w
    walkerbill76
    $SLS conversation
    Joe last year Replied to a reaction
    $SLS conversation
    @CS1001 what's in 3 years? the Two Checkpoint combination readouts, Keytruda / Opdivo + Gps are in May or June - Then the Nps Her2 3+ trial like the $GLSI trial that sent the market cap from 50M to 1.5B in a Single Day that trial gets published in Nov and then of course the phase 3 is in 10 months with the FDA approval in that time frame ///
    -----------------------------------------------------------------------

    Time for your apology, "Joe". How many families did you destroy? How many retirements did you cancel? How many college funds did you empty?

    You were still pumping NPS long after the company knew it was a failure.
  • J
    Jim jr
    I am mostly invested in oil and commodities. I came across SLS while looking into Greenwhich life-science and buying some of their shares. I then saw Immuno investor10's pumping posts on their page promising +2500% gain by early 2021 (which never happened). He has since "disappeared".

    The style of writing between Immune 10 and Cured are almost identical. Having noticed this similarity and the constant pumping posts that did not exist in greenwhich convinced me SLS is a scam and to stick with $GLSI only
  • H
    History101
    building a position, $9.35. 9/28/22
  • C
    Cured
    $SLS conversation
    Can you research my posts for the time before $glsi was up 2,400% in a single trading session. p2 data presented at sabcs was published 5 months before the market took notice. I think the market is missing number 1.of 8 on the catalyst list. Final phase 2, 3 year old joint analysis - Checkpoint blockade + wt1 t cells, final results could be in the next 2 days, based Gabrieles posts. A late breaking abstract Pr could take this 40m mcap to 100 or 400 if Merck puts in upfront money for a license. Last update - median survival not yet met at 10m of survival, with no black bx SA's. Already an effective treatment.
  • C
    Cured
    $SLS conversation
    You can look back at my posts from the fall of 2019 at 1.87 before the run to $19. Gps published 2 p2, launching bmy mrk trials and a p3, covid closed the hospitals, and we are right back to then, when the stock climbed to 19, similar Set up as now.
    Of course, big differences now include timing- the clock keeps running, being fully funded, multiple efficacy signals, a majorly undervalued share price considering the potential revenue.

    I had 40 posts $GLSI before it Launched 2,469% in a single day, was posting about the earlier trial data - that then got published - it was year old Peptide Immunotherapy data presented at SABcs.
    I was posting then much as now, that markets are inefficient at times.

    I think $sls is ready for launch.
  • s
    sWINger
    One of my favorite facts, GLSI Moved 2,469% in one day based on public data, that had been published and well known by a few of us ;) for many months.
    $SLS is next

    $XBI $LABU
  • A
    Anthony
    If all goes well over the next 5 years and we make it to production and sales..... What is this likely to be per share?
  • T
    Tacadena
    (http://bullishstocks.tech) is a must for any trader. Their watchlist which covers pre-market movers is one of the best researched in the industry.
  • L
    Liz
    My friend passed away from metastatic breast cancer a few years back. Olivia Newton John passed away from it last week. Countless mothers, daughters, sisters, family members and friends have had it, have it or chances of it coming back without a viable outcome. It is a horrible disease. Praying for all and hopefully we will have a cure.
  • H
    History101
    per Barron's, short position is 23.1% of float
  • S
    Stephens
    $SLS conversation
    $SLS's GPS is a majorly under valued p3 asset
    The company $GLSI said before the open that a poster presentation of five-year data for the GP2 clinical trial met all of its endpoints and showed zero recurrence of breast cancer in patients who had previously undergone surgery. The stock, which went public on Sept. 25, was now trading 2,159.7% above its $5.75 initial public offering price. The stock was soaring on a day that the iShares Nasdaq Biotechnology ETF IBB,
  • s
    sujeendran
    hault? not moving.....
  • R
    RedChip
    Join our live webinar today, Aug 16, at 4:15 PM Eastern, with Greenwich LifeSciences (NASDAQ: GLSI). You'll hear from CEO Snehal Patel and can participate in an interactive Q&A session.

    https://redchip.zoom.us/webinar/register/WN_9YGrXMi-QX-2_7HStDkb9Q
  • g
    greg
    $SLS conversation
    Potential for an early idmc halt for efficacy is a serious reality.
    Take a look a look at the bio statistician, and his ability to call it, if there is a clear signal.
    Were it to happen, SLS shares would immediately trade up to $75 per share or more. $glsi ran from 5 to 150 in a single day - and that was a P2.

    SELLAS Establishes Independent Data Monitoring Committee of Leading Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial
    05/18/20 Independent Data Monitoring Committee (DMC) to Review and Evaluate Patient Safety and Efficacy Data for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second Remission
    Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center to serve as DMC Chair
    Thomas Fleming, Ph.D., Professor and former biostatistics department chair of the University of Washington, Member of the Fred Hutchinson Cancer Research Center, Special Government Employee for the FDA, and a regular member of FDA Advisory Committees to serve as Lead Biostatistician on DMC
    NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced the formation of the Independent Data Monitoring Committee (DMC) for its pivotal Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) who have achieved complete remission after second-line anti-leukemic therapy (CR2).

    The DMC is comprised of an independent group of medical, scientific and biostatistics experts and is responsible for reviewing and evaluating patient safety and efficacy data for the Company's Phase 3 REGAL clinical trial. The DMC will review study data at regular intervals in order to ensure the safety of all patients enrolled in the study. The Committee will also monitor the quality and overall conduct and ensure the validity, scientific and clinical merits of the study, including each site's compliance with the requirements specified in the study protocol. The DMC is charged with assessing such actions in light of an acceptable benefit/risk profile for GPS and will also make applicable recommendations regarding the clinical trial to SELLAS.

    “Our REGAL clinical trial is the only Phase 3 study focused on remission prolongation through maintenance post-CR2 therapy, a significant and growing unmet medical need. As such, it is critically important to maintain the highest levels of integrity for this pivotal study. With the formation of the DMC, comprised of highly regarded and experienced physicians and biostatisticians who will confer with the respected physicians on the Steering Committee recently announced, we believe that we have brought together world class experts to monitor and guide this critical study which has the potential to extend the life of AML patients in CR2,” said Angelos Stergiou, MD, ScD h.c., President & Chief Executive Officer of SELLAS. “Furthermore, the DMC will be able, at its sole discretion, to directly and independently liaise with the U.S. Food and Drug Administration (FDA) in order to discuss potential early unblinding and discontinuation of the study in case of reliable evidence of safety and clinically significant positive efficacy of GPS. We believe that this further strengthens the integrity and conduct of our REGAL study.”

    The Data Monitoring Committee currently consists of four members:

    Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center and Chair of the REGAL Data Monitoring Committee
    Thomas Fleming, Ph.D., Professor and former department chair of the University of Washington Department of Biostatistics, Member of the Fred Hutchinson Cancer Research Center, former Director of the Statistical Center for HIV/AIDS Prevention Trial Network, NIAID, Special Government Employee for the FDA, and for more than 25 years, a regular member of several FDA Advisory Committees
    Miguel-Angel Perales, M.D., Chief, Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center (MSKCC)
    Stephane de Botton, M.D., Head of the Hematology Department at the Gustave Roussy Cancer Campus in Paris, France
    Dr. Moshe Talpaz, commented, “I look forward to working together with the other esteemed members of the Data Monitoring Committee

    https://www.sellaslifesciences.com/investors/news/News-Details/2020/SELLAS-Establishes-Independent-Data-Monitoring-Committee-of-Leading-Clinical-and-Biostatistics-Experts-for-Pivotal-Phase-3-REGAL-Clinical-Trial/default.aspx
    $XBI
  • C
    CoolQ
    This stock will be a swing traders wet dream for the next 7 years.
  • J
    John
    Thanks Liz. My wife's sister was recently diagnosed with breast cancer. When I look at the comments sometimes on this board and people talking about shorting and trashing a company that wants to help women and some men live disease free all I can do is shake my head. It's disgusting. It's not a game. Very sad. God bless all.